Literature DB >> 3165742

Chronic myelomonocytic leukemia and primary Sjögren's syndrome.

T Ponge1, F Champetier de Ribes, A Ponge, R Garand, S Cottin.   

Abstract

Although associations of Sjögren's syndrome (SS) with malignant affections are well known, an association with chronic myelomonocytic leukemia (CMML) is infrequent. Our report concerns an 80-year-old woman with chronic polyarthrosis, hospitalized for an anemic syndrome, who also complained of buccal dryness. Clinical examination showed simply parotid swelling and discrete splenomegaly. The diagnosis of SS appeared to be primary. The hemogram, myelogram and bone biopsy indicated CMML. During SS, the possibility of occurrence of a lymphoproliferative syndrome is well documented, and other malignant affections are much less likely to be found in the absence of immunosuppressive treatment. The particular case of SS and associated CMML detected at the same time suggests either the favorable role of monocytic proliferation on immunity or a stem clonal anomaly affecting monocytes and B lymphocytes.

Entities:  

Mesh:

Year:  1988        PMID: 3165742     DOI: 10.1007/bf02284066

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

1.  Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease.

Authors:  R R Love; J M Sowa
Journal:  Ann Rheum Dis       Date:  1975-12       Impact factor: 19.103

Review 2.  Hematopoietic stem cells.

Authors:  P Quesenberry; L Levitt
Journal:  N Engl J Med       Date:  1979-10-04       Impact factor: 91.245

3.  [Rheumatoid polyarthritis, Gougerot-Sjögren syndrome and chronic myeloid leukemia. Apropos of 2 cases].

Authors:  C Job-Deslandre; C J Menkès; B Michalski; F Tessier
Journal:  Rev Rhum Mal Osteoartic       Date:  1985-04

4.  Sjögren's syndrome associated with chronic lymphocytic leukemia.

Authors:  A Bán; S Ferenczy
Journal:  Panminerva Med       Date:  1984 Jul-Sep       Impact factor: 5.197

5.  The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome.

Authors:  L G Anderson; N Talal
Journal:  Clin Exp Immunol       Date:  1972-02       Impact factor: 4.330

6.  Extrasalivary lymphoid abnormalities in Sjögren's syndrome (reticulum cell sarcoma, "pseudolymphoma," macroglobulinemia).

Authors:  N Talal; L Sokoloff; W F Barth
Journal:  Am J Med       Date:  1967-07       Impact factor: 4.965

7.  Controlled trial of cyclophosphamide in rheumatoid arthritis.

Authors:  A S Townes; J M Sowa; L E Shulman
Journal:  Arthritis Rheum       Date:  1976 May-Jun

8.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

9.  Acute leukemia following cyclophosphamide therapy for Sjögren's syndrome.

Authors:  M C Hochberg; L E Shulman
Journal:  Johns Hopkins Med J       Date:  1978-06

10.  Sjögren's syndrome terminating as a myeloproliferative disorder.

Authors:  W E DeCoteau; S B Katakkar; L Skinnider; R C Hayton; E A Somerville
Journal:  J Rheumatol       Date:  1975-09       Impact factor: 4.666

View more
  2 in total

Review 1.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

2.  A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects.

Authors:  M Pertovaara; E Pukkala; P Laippala; A Miettinen; A Pasternack
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.